U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Relenza (zanamivir) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Relenza (zanamivir) Information

Relenza (zanamivir) is an inhalation powder for oral inhalation approved for treatment of acute uncomplicated illness due to influenza A and B virus in adults and pediatric patients aged 7 years of age and older who have been symptomatic for no more than 2 days.

Relenza is indicated for preventive use (prophylaxis) in adults and pediatric patients aged 5 years of age and older.

Relenza is not a substitute for early influenza vaccination on an annual basis.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Related Information

Labeling and Regulatory History from Drugs@FDA

ResourcesForYou

Back to Top